<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841137</url>
  </required_header>
  <id_info>
    <org_study_id>16CDN-Prg02</org_study_id>
    <nct_id>NCT02841137</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Progesterone Tablet in Post-menopausal Women</brief_title>
  <official_title>Effect of Progesterone 5, 10, and 20 mg Tablets Compared To Progesterone 100 mg Capsules on the Endometrial Thickness of Post-Menopausal Women Under Hormone Therapy - A Prospective, Open-Label, Randomized, Four-Arm, Parallel-Group, Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study intended to determine the effect of progesterone 5, 10 and 20 mg&#xD;
      tablets compared to progesterone 100 mg capsules on the endometrial thickness of&#xD;
      post-menopausal women under hormone therapy with estradiol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">April 25, 2018</completion_date>
  <primary_completion_date type="Actual">August 2, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endometrial thickness change towards baseline (mm)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>histological assessment of the endometrium (presence of hyperplasia or proliferation)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding (presence or absence)</measure>
    <time_frame>everyday over 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (MENQOL Questionnaire)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep scale from the Medical Outcomes Study (MOS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>progesterone 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>progesterone 5 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progesterone 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>progesterone 10 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progesterone 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>progesterone 20 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progesterone 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>progesterone 100 mg capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>comparison of different dosages of drug towards the active comparator</description>
    <arm_group_label>progesterone 10 mg</arm_group_label>
    <arm_group_label>progesterone 100 mg</arm_group_label>
    <arm_group_label>progesterone 20 mg</arm_group_label>
    <arm_group_label>progesterone 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Availability for the entire study period&#xD;
&#xD;
          2. Post-menopausal female defined as:&#xD;
&#xD;
               -  at least 12 consecutive months of spontaneous amenorrhea and&#xD;
&#xD;
               -  less than 10 years of spontaneous amenorrhea, and&#xD;
&#xD;
               -  Follicle-stimulating hormone (FSH) levels &gt; 40 milli International Units/ml&#xD;
&#xD;
          3. Females with an intact uterus&#xD;
&#xD;
          4. Moderate to severe climacteric vasomotor symptoms&#xD;
&#xD;
          5. Aged of at least 40 years but not older than 65 years&#xD;
&#xD;
          6. Body mass index (BMI) greater than or equal to 18.00 kg/m2 and below 30.00 kg/m2&#xD;
&#xD;
          7. Non- or ex-smoker;&#xD;
&#xD;
          8. Endometrium thickness â‰¤4 mm on ultrasonography at screening&#xD;
&#xD;
          9. Negative mammogram (dated &lt; 2 years)&#xD;
&#xD;
         10. Negative Pap smear test (dated &lt; 1 year)&#xD;
&#xD;
         11. Normal clinical breast examination&#xD;
&#xD;
         12. Normal pelvic examination&#xD;
&#xD;
         13. Have no clinically significant diseases captured in the medical history or evidence of&#xD;
             clinically significant findings on physical examination, as determined by the medical&#xD;
             investigator&#xD;
&#xD;
         14. Willingness to adhere to the protocol requirements as evidenced by the informed&#xD;
             consent form (ICF) duly read, signed and dated by the subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any estrogen, progestin, or estrogen/progestin drug products, androgens,&#xD;
             selective estrogen receptor modulators (SERMs), phytoestrogen supplements or natural&#xD;
             products (soy, black cohosh, dong quai) during the past 3 months before the screening&#xD;
             visit&#xD;
&#xD;
          2. Use of any estrogen, progestin or androgen pellet or injectable therapy during the&#xD;
             past 6 months before the screening visit&#xD;
&#xD;
          3. Contraindications to hormone therapy:&#xD;
&#xD;
               -  Active liver dysfunction or disease or history of severe liver disease&#xD;
&#xD;
               -  Known, suspected or past history of hepatic tumors (benign or malign)&#xD;
&#xD;
               -  Active or past history of arterial thromboembolic disease (e.g. angina,&#xD;
                  myocardial infarction, stroke, coronary heart disease, transient ischemic attack)&#xD;
&#xD;
               -  Active or past history of venous thromboembolism (e.g. deep venous thrombosis,&#xD;
                  pulmonary embolism) or active thrombophlebitis&#xD;
&#xD;
               -  Known, suspected or past history of breast cancer&#xD;
&#xD;
               -  Known, suspected or past history of estrogen-dependent or progestin-dependent&#xD;
                  malignant neoplasia (e.g. endometrial cancer)&#xD;
&#xD;
               -  Endometrial hyperplasia&#xD;
&#xD;
               -  Porphyria cutanea tarda&#xD;
&#xD;
               -  Genital bleeding&#xD;
&#xD;
               -  Untreated hypertension&#xD;
&#xD;
               -  Classical migraine&#xD;
&#xD;
               -  Partial or complete loss of vision or diplopia due to ophthalmic vascular disease&#xD;
&#xD;
          4. Presence of clinically significant screening ECG abnormalities as defined by medical&#xD;
             judgment&#xD;
&#xD;
          5. Presence of polyps&#xD;
&#xD;
          6. Presence of uterine fibroids or other abnormalities affecting endometrial thickness&#xD;
             measurement or precluding estrogen therapy&#xD;
&#xD;
          7. Known hypersensitivity to the active substances or to any of the excipients contained&#xD;
             in the drug products in particular to soya or peanut, as well as hereditary problems&#xD;
             of fructose intolerance or phenylketonuria&#xD;
&#xD;
          8. Participation in a concurrent clinical trial or another trial within the past 2 months&#xD;
&#xD;
          9. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450&#xD;
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,&#xD;
             fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP&#xD;
             enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and&#xD;
             St John's Wort), in the previous 28 days before day 1 of this study&#xD;
&#xD;
         10. Maintenance therapy with any drug or significant history of drug dependency, drug&#xD;
             abuse or alcohol abuse within the last 2 years&#xD;
&#xD;
         11. Presence of any medical condition or other circumstances which would significantly&#xD;
             decrease the chance of obtaining reliable data, achieving study objectives or&#xD;
             completing the study&#xD;
&#xD;
         12. Serious psychiatric problems (whether or not receiving treatment) or in any case such&#xD;
             as to compromise the patient's reliability&#xD;
&#xD;
         13. Any clinically significant illness in the previous 28 days before day 1 of this study&#xD;
&#xD;
         14. Any history of tuberculosis and/or prophylaxis for tuberculosis&#xD;
&#xD;
         15. Positive screening of alcohol and/or drugs of abuse&#xD;
&#xD;
         16. Positive results to HIV Ag/Ab combo, hepatitis B surface antigen or hepatitis C virus&#xD;
             tests&#xD;
&#xD;
         17. Females who are pregnant according to a positive serum pregnancy test&#xD;
&#xD;
         18. Presumption of subject's poor reliability/cooperation&#xD;
&#xD;
         19. Any reason which, in the opinion of the Investigator, would prevent the subject from&#xD;
             participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deschamps</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma</name>
      <address>
        <city>Mont-Royal</city>
        <state>Quebec</state>
        <zip>H3P3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>June 8, 2018</last_update_submitted>
  <last_update_submitted_qc>June 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

